Elicio Therapeutics, Inc (ELTX)
NASDAQ:ELTX
Want to see ELTX full AI Analyst Report?
ELTX Stock Chart & Stats
$13.55
$0.10(1.66%)
At close: 4:00 PM EST
$13.55
$0.10(1.66%)
Day’s Range― - ―
52-Week Range$2.66 - $16.00
Previous CloseN/A
Volume37.28K
Average Volume (3M)577.75K
Market Cap
$52.68M
Enterprise Value$89.29M
Total Cash (Recent Filing)$14.95M
Total Debt (Recent Filing)$14.34M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Aug 07, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.36
Shares Outstanding19,086,080
10 Day Avg. Volume1,458,369
30 Day Avg. Volume577,751
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)74.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.30
Enterprise Value/Market Cap1.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-308.95
Enterprise Value/Ebitda-2.37
Forecast
1Y Price Target
$20.67Price Target Upside52.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biological Activity & Biomarker CorrelationDemonstrated correlation between mKRAS-specific T-cell responses and better outcomes indicates a clear on‑target biological mechanism and a potential predictive biomarker. That durable mechanistic signal can enable enriched trial designs and improve probability of success in registrational studies.
Potential Checkpoint Synergy (immune Priming)Observed durable complete responses after subsequent anti–PD‑1 therapy suggest ELI‑002 may prime tumors to respond to checkpoint inhibitors. If replicated prospectively, this structural synergy could expand indications, enable efficient combo trials, and attract partnership interest.
Refined Registrational Strategy Focused On R0 SubgroupShifting to a focused Phase 3 in R0 resected patients and adjusting dosing/endpoint reduces patient heterogeneity and targets the subgroup with strongest signal. This strategic refinement increases statistical power and the likelihood of a clear regulatory path if the subgroup effect is real.
Bears Say
No Revenue And Persistent Cash BurnThe company has no product revenue and sustained large operating and free cash flow deficits, requiring recurring external financing. Persistent cash burn limits runway, increases dilution risk, and constrains the firm's ability to execute multi‑stage clinical programs independently.
Weakened Balance Sheet / Negative EquityNegative equity and a small asset base reflect accumulated losses that erode the capital cushion. Moderate absolute debt combined with negative equity raises leverage and reduces flexibility to absorb setbacks, making the company more dependent on dilutive financing or strategic partners.
Missed Phase 2 Primary Endpoint; Reliance On Post‑hoc SignalsFailing the intent‑to‑treat primary endpoint weakens the statistical case for efficacy and raises regulatory risk. Reliance on post‑hoc and subgroup analyses makes registrational success contingent on confirmatory data and increases the need for additional financing to run redesigned trials.
Elicio Therapeutics News
ELTX FAQ
What was Elicio Therapeutics, Inc’s price range in the past 12 months?
Elicio Therapeutics, Inc lowest stock price was $2.66 and its highest was $16.00 in the past 12 months.
What is Elicio Therapeutics, Inc’s market cap?
Elicio Therapeutics, Inc’s market cap is $52.68M.
When is Elicio Therapeutics, Inc’s upcoming earnings report date?
Elicio Therapeutics, Inc’s upcoming earnings report date is Aug 07, 2026 which is in 50 days.
How were Elicio Therapeutics, Inc’s earnings last quarter?
Elicio Therapeutics, Inc released its earnings results on May 11, 2026. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.465 by -$0.185.
Is Elicio Therapeutics, Inc overvalued?
According to Wall Street analysts Elicio Therapeutics, Inc’s price is currently Undervalued.
Does Elicio Therapeutics, Inc pay dividends?
Elicio Therapeutics, Inc does not currently pay dividends.
What is Elicio Therapeutics, Inc’s EPS estimate?
Elicio Therapeutics, Inc’s EPS estimate is -0.54.
How many shares outstanding does Elicio Therapeutics, Inc have?
Elicio Therapeutics, Inc has 19,086,080 shares outstanding.
What happened to Elicio Therapeutics, Inc’s price movement after its last earnings report?
Elicio Therapeutics, Inc reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.465. Following the earnings report the stock price went down -9.13%.
Which hedge fund is a major shareholder of Elicio Therapeutics, Inc?
Currently, no hedge funds are holding shares in ELTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elicio Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.67 (52.52% Upside)
$20.67 (52.52% Upside)
Blogger Sentiment
Bearish
ELTX Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 24.9%
Last 30 Days ▲ 35.3%
Last 30 Days ▲ 35.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 40%
Bearish news 40%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-40.75%
12-Months-Change
Fundamentals
Return on Equity
-2748.16%
Trailing 12-Months
Asset Growth
-19.38%
Trailing 12-Months
Company Description
Elicio Therapeutics, Inc
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
ELTX Stock 12 Month Forecast
Average Price Target
$20.67
▲(52.52% Upside)
Technical Analysis
Compugen
―
―
Seres Therapeutics
―
Milestone Pharmaceuticals
―
Actuate Therapeutics, Inc.
―
Ownership Overview
1.17% Insiders
3.30% Mutual Funds
4.40% Other Institutional Investors
88.30% Public Companies and
Individual Investors